Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29747
Title: Serious Cardiac Arrhythmias Detected by Subcutaneous Long-term Cardiac Monitors in Patients With Drug-Resistant Epilepsy.
Austin Authors: Sivathamboo, Shobi;Liu, Zining;Sutherland, Fiona;Minato, Erica;Casillas-Espinosa, Pablo;Jones, Nigel C;Todaro, Marian;Seneviratne, Udaya;Cahill, Varduhi;Yerra, Raju;French, Christopher;Nicolo, John-Paul;Perucca, Piero ;Kwan, Patrick;Sparks, Paul;O'Brien, Terence J
Affiliation: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, 3004, Victoria, Australia..
Department of Neurology, The Alfred Hospital, Melbourne, 3004, Victoria, Australia..
Department of Cardiology, The Royal Melbourne Hospital, Parkville, 3050, Victoria, Australia..
Department of Neurology, Monash Medical Centre, Clayton, 3168, Victoria, Australia..
Manchester Centre for Clinical Neurosciences, Salford Royal Hospital NHS Foundation Trust, Stott Lane, Salford M6 8HD, United Kingdom..
Department of Neurology, The Royal Melbourne Hospital, Parkville, 3050, Victoria, Australia..
Comprehensive Epilepsy Program
Medicine (University of Melbourne)
Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Parkville, 3050, Victoria, Australia..
Division of Neuroscience and Experimental Psychology, School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom..
Issue Date: 2022
metadata.dc.date: 2022-04-06
Publication information: Neurology 2022; 98(19): e1923-e1932
Abstract: Epilepsy is associated with an increased risk of cardiovascular disease and premature mortality, including sudden unexpected death in epilepsy (SUDEP). Of concern, serious cardiac arrythmias might go undetected from routine epilepsy and cardiac investigations. This prospective cohort study aimed to detect cardiac arrhythmias in patients with chronic drug-resistant epilepsy (≥5 years duration) using subcutaneous cardiac monitors for a minimum follow-up duration of 12 months. Participants with known cardiovascular disease or those with abnormal 12-lead electrocardiograms were excluded. The device was programmed to automatically record episodes of tachycardia ≥140 beats per minute (bpm), bradycardia ≤40 bpm for ≥3 seconds, or asystole ≥3 seconds. Thirty-one patients underwent subcutaneous cardiac monitoring for a median recording duration of 2.2 years (range 0.5 to 4.2). During this time, 28 (90.3%) patients had episodes of sustained (≥30s) sinus tachycardia, 8/31 (25.8%) had sinus bradycardia, and 3 (9.7%) had asystole. Three (9.7%) patients had serious cardiac arrhythmias requiring additional cardiac interventions. Among them, two patients had prolonged sinus arrest and ventricular asystole (>6 seconds), leading to pacemaker insertion in one; and another patient with an epileptic encephalopathy had multiple episodes of recurrent non-sustained polymorphic ventricular tachycardia and bundle branch conduction abnormalities. The time to first detection of a clinically significant cardiac arrhythmia ranged between 1.2 to 26.9 months following cardiac monitor insertion. Implantable cardiac monitors detected a high incidence of clinically significant cardiac arrhythmias in patients with chronic drug resistant epilepsy, which may contribute to the incidence of premature mortality including SUDEP.
URI: https://ahro.austin.org.au/austinjspui/handle/1/29747
DOI: 10.1212/WNL.0000000000200173
ORCID: 0000-0002-7855-7066
Journal: Neurology
PubMed URL: 35387849
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35387849/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Jun 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.